Core Viewpoint - Despite major market indexes like the S&P 500 struggling in 2025, certain mid-cap stocks in the medical and biotechnology sectors are showing strong performance and growth potential, presenting investment opportunities for those looking beyond large-cap stocks [1]. Group 1: Penumbra - Penumbra, Inc. is a high-growth medical devices company with a market capitalization of $11.3 billion, focusing on neuro and vascular interventions [2][3]. - The stock has increased by 23% year-to-date and 43% over the past 12 months, demonstrating resilience amid broader market volatility [2][3]. - The company reported Q1 earnings of $0.83 per share, exceeding estimates by $0.17, with revenue rising 16.3% year-over-year to $324.1 million [3]. - Analysts maintain a Moderate Buy consensus rating, with a price target of $302.40, indicating further upside potential [4]. Group 2: TransMedics Group - TransMedics Group is a commercial-stage medical technology company focused on organ transplant procedures, with a market cap of $92.18 million [6]. - The stock has surged nearly 48% year-to-date, following a breakout above key resistance levels [7]. - Analysts have a Moderate Buy consensus rating, with a price target of $124.20, suggesting up to 35% upside from current levels [8]. Group 3: ADMA Biologics - ADMA Biologics is a biopharmaceutical company specializing in plasma-derived biologics, with a market capitalization of $5.6 billion [10]. - The stock has risen 38% year-to-date and is trading just 7% below its all-time high [10][11]. - The company has a P/E ratio of 29 and a forward P/E of 23, with projected EPS growth of 45% in 2025, supported by a Buy rating from all four analysts covering the stock [11].

Market Overview - The three major U.S. indexes (Nasdaq Composite, S&P 500, Dow Jones Industrial Average) ended the past trading week positively, with gains of 3.52%, 2.86%, and 3.41% respectively [1] - Despite a gloomy economic outlook due to shifts in U.S. foreign tariff policy, weak economic data, and rising geopolitical tensions, investors are optimistic about strong earnings results and potential reductions in import duties by the Trump administration [1] Economic Indicators - The U.S. GDP contracted for the first time in three years, growing at an annualized rate of 0.3% in Q1 2025, down from 2.4% in the previous quarter [2] - Consumer sentiment index dropped to 52.2 in April from 57.0 in March, marking the lowest level since July 2022 [2] - The consumer confidence index fell to 86 in April from 92.9 in March [2] - The Personal Consumption Expenditure (PCE) index remained flat in March, while personal consumption and personal income grew by 0.7% and 0.5% respectively, exceeding expectations [2] Manufacturing and Labor Market - The manufacturing PMI for April contracted to 48.7% from 49% in March, indicating contraction in manufacturing activities [3] - Nonfarm payrolls increased by 177,000 in April, exceeding analyst expectations, while the unemployment rate remained unchanged at 4.2% [3] Stock Performance and Recommendations - ADMA Biologics, Inc. shares gained 48.6% since being upgraded to Zacks Rank 2 (Buy) on March 4, outperforming the S&P 500's 3% decrease [4] - Intrepid Potash, Inc. shares returned 28.9% since its upgrade to Zacks Rank 2 on March 6, also outperforming the S&P 500 [5] - The Zacks Model Portfolio of Rank 1 stocks has outperformed the S&P 500 index by almost 13 percentage points since 1988, with an annualized average return of +23.9% [7] Focus List and Portfolios - Constellation Brands, Inc. gained 8.2% over the past 12 weeks, while Cheniere Energy, Inc. returned 2.3% during the same period [11] - The Zacks Focus List portfolio returned -2.96% in Q1 2025, compared to -4.30% for the S&P 500 index [12] - The Zacks Earnings Certain Admiral Portfolio (ECAP) returned +3.20% in Q1 2025, outperforming the S&P 500 index's -4.30% decline [16] Dividend and Defensive Stocks - Coca-Cola Company returned 13.5% over the past 12 weeks, while Quest Diagnostics Incorporated increased by 7.9% [18] - The Zacks Earnings Certain Dividend Portfolio (ECDP) returned +5.74% in Q1 2025, outperforming the S&P 500 index's -2.41% pullback [19] Top 10 Stocks Performance - Primo Brands Corporation increased by 7.4% year-to-date, compared to the S&P 500 index's 3.3% decrease [22] - The Top 10 portfolio returned +62.98% in 2024, significantly outperforming the S&P 500 index's +25.04% return [22][23]

Group 1 - Adma Biologics closed at $23.52, with a +1.07% change, underperforming the S&P 500's daily gain of 1.47% [1] - Over the past month, shares of Adma Biologics gained 19.64%, outperforming the Medical sector's loss of 2.95% and the S&P 500's loss of 0.47% [1] Group 2 - The upcoming earnings release on May 7, 2025, is expected to show an EPS of $0.16, a 100% increase from the same quarter last year, with projected net sales of $119.1 million, up 45.46% year-over-year [2] - For the full year, analysts expect earnings of $0.71 per share and revenue of $495.8 million, reflecting changes of +44.9% and +16.26% respectively from the previous year [3] Group 3 - Changes in analyst estimates for Adma Biologics are important as they reflect short-term business trends and analysts' confidence in the company's performance [4] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), indicates that Adma Biologics currently holds a Zacks Rank of 2 (Buy) [6] Group 4 - Adma Biologics has a Forward P/E ratio of 32.78, which is a premium compared to the industry average Forward P/E of 17.32 [7] - The Medical - Biomedical and Genetics industry, which includes Adma Biologics, holds a Zacks Industry Rank of 84, placing it in the top 35% of over 250 industries [7]

Core Viewpoint - ADMA Biologics is expected to report first-quarter 2025 results on May 7, with sales estimated at $119.1 million and earnings at 16 cents per share, reflecting a positive trend in earnings estimates for 2025 and 2026 [1][2][16]. Financial Performance - The earnings estimate for 2025 has increased to 71 cents from 69 cents per share over the past 60 days, while the estimate for 2026 has improved to 93 cents from 87 cents [1][2]. - ADMA has a mixed earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 32.8%, although it missed estimates by 6.67% in the most recent quarter [2][3]. Product Overview - ADMA markets plasma-derived biologics, including three FDA-approved products: Bivigam, Asceniv, and Nabi-HB, aimed at treating immune deficiencies and preventing infectious diseases [6][17]. - Asceniv, the lead product, is a plasma-derived IVIG that contains polyclonal antibodies to neutralize microbes and prevent infections [7][8]. Sales and Growth Drivers - Increased sales of Asceniv are expected to drive revenue growth in the first quarter, supported by a favorable mix of high-margin immunoglobulin sales [9]. - ADMA anticipates significant growth in revenues, projecting over $490 million in 2025 and $605 million in 2026, with net income expected to exceed $175 million in 2025 [16]. Market Position and Strategy - ADMA has entered into long-term high-titer plasma supply contracts, increasing access to raw materials and potentially achieving $1 billion in annual revenues by 2030 [14]. - The company competes with Takeda and Grifols in the U.S. plasma-derived products market and is positioned for substantial growth in the underserved immune-compromised patient population [17][18]. Valuation - ADMA's shares currently trade at a price/sales ratio of 10.59x forward sales, significantly higher than its historical mean of 3.32x and the industry average of 1.76x, indicating a premium valuation [12]. Price Performance - ADMA's stock has surged 38.8% year-to-date, outperforming the industry, which has declined by 2.7% [10].

Group 1 - Adma Biologics (ADMA) has shown a year-to-date return of 38.8%, significantly outperforming the average return of -1.2% for the Medical sector [4] - The Zacks Consensus Estimate for ADMA's full-year earnings has increased by 3.7% over the past three months, indicating improved analyst sentiment and earnings outlook [4] - Adma Biologics is ranked 2 (Buy) in the Zacks Rank system, which highlights stocks with characteristics likely to outperform the market in the near term [3] Group 2 - Adma Biologics is part of the Medical - Biomedical and Genetics industry, which has an average return of -1.8% this year, further showcasing ADMA's strong performance relative to its peers [6] - Another notable stock in the Medical sector is Agilon Health (AGL), which has returned 124.2% year-to-date and also holds a Zacks Rank of 2 (Buy) [5] - The Medical Services industry, to which Agilon Health belongs, has a current ranking of 68 and has experienced a return of -0.8% this year [6]

Adma Biologics (ADMA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this infectious disease drug developer have returned +17.7% over the past month versus the Zacks S&P 500 composite's -0.7% change. The Zacks Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has lost 1.6% over this period. Now the key question is: Where could ...

Wall Street has witnessed severe volatility in 2025 after recording an astonishing bull run in the last two years. Year to date, all three major stock indexes — the Dow, the S&P 500 and the Nasdaq Composite — are in negative territory. The small-cap benchmarks — the Russell 2000 and the S&P 600 — are also in the negative zone year to date. Similarly, the mid-cap-specific S&P 400 Index is also in the red.Despite this headwind, a handful of mid-cap stocks are flying high providing more than 25% returns year t ...

Conference Call Scheduled for May 7, 2025, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2025 financial results on May 7, 2025, after the U.S. financial markets close. ADMA’s management team will host a live conference call ...

Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA's Uniquely Efficient Internal R&D Engine, Spanning Production and Product Development Capabilities Anticipate Approximately 20% Production Output Enhancement from Same Starting Plasma Volume About ADMA Biologics, Inc. (ADMA) ADMA Biologics is a U.S. based, end-to-end commercial biopharmaceutica ...

Group 1 - Adma Biologics (ADMA) closed at $21.31, with a +0.38% change from the previous day, outperforming the S&P 500's gain of 0.13% [1] - Over the past month, ADMA shares have appreciated by 3.01%, while the Medical sector lost 8.46% and the S&P 500 lost 6.3% [1] Group 2 - The upcoming financial results for Adma Biologics are anticipated to show an EPS of $0.16, reflecting a 100% increase from the same quarter last year [2] - Revenue is forecasted to be $119.1 million, indicating a growth of 45.46% compared to the corresponding quarter of the prior year [2] Group 3 - Full-year Zacks Consensus Estimates predict earnings of $0.71 per share and revenue of $495.8 million, representing year-over-year changes of +44.9% and +16.26%, respectively [3] - Recent adjustments to analyst estimates for Adma Biologics indicate positive sentiment regarding the company's business and profitability [3] Group 4 - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that stocks rated 1 deliver an average annual return of +25% since 1988 [5] - Over the past month, the Zacks Consensus EPS estimate for Adma Biologics has increased by 2.16%, and the company currently holds a Zacks Rank of 2 (Buy) [5] Group 5 - Adma Biologics has a Forward P/E ratio of 29.9, which is a premium compared to the industry average Forward P/E of 15.68 [6] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 76, placing it in the top 31% of over 250 industries [6]